Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I (2013). Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill 18(40)
Crossref

Balabanova Y, Radiulyte B, Davidaviciene E (2011). Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open 1:e000351
Crossref

Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN (2007). Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures. PLoS ONE 2(11)
Crossref

Dennis F, Fuad M, Fraser W, Inés B, Matteo Z, Nguyen L (2015). Multidrug-resistant tuberculosis around the world: what progress has been made?. Europe Respiration Journal 45:150-160
Crossref

Farley JE, Ram M, Pan W, Waldman S, Cassell GH (2011). Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PLoS ONE 6(7):e20436.
Crossref

Federal Ministry of Health of Ethiopia (FMOH). (2009). Guideline for program and clinical management of drug resistant tuberculosis. Addis Ababa: FMOH.

FMOH (2011). Participants' Manual: national comprehensive tuberculosis, leprosy and TB/HIV training for general health workers. Addis Ababa: FMOH.

Getachew T, Bayray A and Weldearegay B (2013). Survival and Predictors of Mortality among Patients under Multi-Drug Resistant Tuberculosis treatment in Ethiopia: St. Peter's specialized Tuberculosis hospital, Ethiopia. International Journal Pharm. Science Research 4(2):776-787.

Girum T, Tariku Y, Dessu S (2017). Survival Status and Treatment Outcome of Multidrug Resistant Tuberculosis (MDR-TB) among Patients Treated in Treatment Initiation Centers (TIC) in South Ethiopia: A Retrospective Cohort Study. Annual Medical Health Science Research 7:331-336

Hussein B, Debebe T, Wilder-Smith A, Ameni G (2013). Drug susceptibility test on M. tuberculosis isolated from pulmonary tuberculosis in three sites of Ethiopia. African Journal Microbiology Research 7(9):791-796

Macarthur C, Stalz CV, Serena P, Lauren M, Marie M, Oksana O (2014). Treatment Outcomes for Patients with Multidrug-Resistant Tuberculosis in Post-Earthquake Port-au-Prince, Haiti. American Journal Tropical. Medical Hygiene 91(4):715-721
Crossref

Meressa D, Hurtado RM, Andrews JR (2015). Achieving high treatment success for multidrugresistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia-an observational cohort study. Thorax Online (207374).
Crossref

Nkhoma WAC, Kibuga D, Salomao A, Keita B, Ndongosieme A, Wembanyama H, Roungou J (2012). Multidrug-resistant and extensively drug-resistant tuberculosis in the African region. African health monitor pp. 24-25.

Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP (2009). Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infectious Disease 9:153-161.
Crossref

Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N (2015). Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. International Journal Tuberculosis Lung Disease 19(8):969-978
Crossref

Sharma SK, Mohan A (2006). Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 130:261-272.
Crossref

Tang S, Tan S, Yao L, Li F, Li L (2013). Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. PLoS ONE 8(12):e82943.
Crossref

The Global Planto Stop (2010). TB2011-2015: transforming the fight towards elimination of tuberculosis. WHO/HTM/STB/2010.2. Geneva, World Health Organization.

Ulmasova D, Uzakova G (2013). Tillyashayhov M, et al. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill 18:20609.
Crossref

World Health Organization (WHO) (2003). Treatment of tuberculosis: Guidelines For national programs; Geneva. 

View

World Health Organization (WHO) (2010a). Multidrug and extensively drug-resistant TB (M/XDR-TB): global report on surveillance and response. Geneva: WHO.

World Health Organization (WHO) (2015). Multidrug-resistant tuberculosis (MDR-TB) 2015 update. Geneva: WHO.

World Health Organization (WHO) (2010b). Global Tuberculosis Control Report; 2010/2011 tuberculosis global facts 

View

World Health Organization (WHO) (2008). Guidelines for the programmatic management of drug-resistance tuberculosis. Geneva, Switzerland.

World Health Organization (WHO) (2011). Tuberculosis MDR-TB & XDR-TB progress report.

Zignol M, van Gemert W, Falzon D (2012). Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 90:111-119D.
Crossref